ADVFN Logo
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover
Premium Connexion/S'inscrire Profile Icon
CAC 40
7 330,47
(
-0,21%
)
Dow Jones
36 245,50
(
0,82%
)
DAX
16 406,43
(
0,05%
)
Brent Oil
78,525
(
-1,37%
)
Bitcoin
41 666,92
(
4,22%
)
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Oragenics Inc (OGEN)

  7. Oragenics Inc (OGEN) Actualités

OGEN Oragenics Inc

3,46
0,00 (0,0%)
Avant marché
Dernière mise à jour : 10:05:01
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Oragenics Inc OGEN AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,0% 3,46 10:05:01
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,46
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/12/202323:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202323:50EDGAR2Form 144 - Report of proposed sale of securities
20/11/202321:45EDGAR2Form 8-K - Current report
16/11/202320:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202312:00EDGAR2Form 8-K - Current report
02/11/202312:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202312:00BWOragenics Issues Update to Shareholders
30/10/202321:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/10/202321:00EDGAR2Form DEF 14A - Other definitive proxy statements
18/10/202314:30BWOragenics Announces Appointment of Bruce Cassidy and John..
06/10/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:28EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/10/202322:25EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/10/202323:29EDGAR2Form 8-K - Current report
05/10/202312:30EDGAR2Form 8-K - Current report
05/10/202312:30BWOragenics to Acquire Odyssey Health’s Neurological Drug..
29/9/202322:00EDGAR2Form 8-K - Current report
29/9/202322:00BWOragenics Enters into Agreement with Lantern Bioworks for..
15/9/202322:00EDGAR2Form 8-K - Current report
18/8/202322:15EDGAR2Form 8-K - Current report
11/8/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:30EDGAR2Form 8-K - Current report
07/8/202314:30BWOragenics, Inc. Announces Private Placement
07/8/202314:09EDGAR2Form 8-K - Current report
05/6/202322:18BWOragenics Project to Develop a Variant-Agnostic Protein..
29/3/202317:45BWOragenics to Participate in the World Vaccine Congress..
14/3/202313:30BWOragenics Announces Positive Results in Several Lantibiotics..
08/3/202315:09BWOragenics Appoints Janet Huffman as Chief Financial Officer..
01/3/202313:30BWOragenics Enters into an Exclusive Global License Agreement..
03/2/202313:30BWOragenics, Inc. Regains Compliance with NYSE American
23/12/202222:05BWOragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
22/12/202213:30BWOragenics Reports Favorable Toxicology Results for its..
20/12/202222:36BWOragenics, Inc. Receives NYSE American Notice
19/12/202222:34BWOragenics, Inc. Announces New Chair

Dernières Valeurs Consultées

AMEX
OGEN
Oragenics
Delayed Upgrade Clock

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Support: support@advfn.fr